Law360, New York (September 03, 2009) -- Endo Pharmaceuticals Inc. has asked a court for permission to intervene in Genzyme Corp.'s Renagel patent infringement case against Impax Laboratories Inc., arguing that Impax challenged a second patent's validity solely in a bid to force first-filer Endo to forfeit its exclusivity period.
In its motion filed Wednesday in the U.S. District Court for the District of Maryland, Endo seeks permission to intervene in order to support Genzyme's motion to dismiss for lack...
